(1 - 24 von 25
)
Merck gibt Start einer klinischen Studie der Phase II/III mit...
www.pressebox.de
Merck KGaA, Studie wird die Sicherheit und Wirksamkeit von Atacicept bei Lupusnephritis untersuchen; sie soll den Antrag auf Marktzu…
Investegate |Merck Serono International SA Announcements | Merck...
www.investegate.co.uk
Investegate announcements from Merck Serono International SA, Merck Serono Announces Initiation of Phase II C...
Merck KGaA starts mid-stage multiple-sclerosis trial | Reuters
www.reuters.com
Merck KGaA has started a mid-stage trial to evaluate the safety and efficacy of atacicept in patients with relapsing multiple sclerosis, the German drugs and...
Grünenthal GmbH presents tapentadol, a novel centrally...
www.ots.at
Tapentadol would be the first new molecular entity in the class of oral centrally acting analgesics to enter medical practice in over 25 years.
Einzigartige Drei-Jahres-Daten über die langfristige Wirksamkeit und...
www.finanznachrichten.de
Langzeit-Sicherheitsprofil", ergänzte Dr. Anton Hoos, Leiter der weltweiten klinischen Entwicklung von Merck Serono. "Dies ist eine wichtige ...
Merck Serono gibt Start einer zweiten klinischen Studie der Phase ...
www.bionity.com
"Atacicept verfügt über das Potenzial, den Verlauf von SLE, einer komplexen und verheerenden Erkrankung, zu beeinflussen", sagte Dr. Anton Hoos, Leiter der weltweiten klinischen Entwicklung von Merck Serono. ...
Merck gibt Start einer zweiten klinischen Studie der Phase II/III ...
www.pressebox.de
— ... sagte Dr. Anton Hoos, Leiter der weltweiten klinischen Entwicklung von Merck Serono. "Diese Studie soll eine Basis zur Beurteilung der ... › Presse › Merck KGaA
FE Investegate |Merck Serono International S A Announcements | Merck...
www.investegate.co.uk
FE Investegate announcements from Merck Serono International S A, Merck Serono Completes Enrollment in the REFLEX...
German Merck KGaA starts mid-stage lupus trial | Reuters
www.reuters.com
"Atacicept has the potential to alter the course of SLE, a complex and devastating disease," said Anton Hoos, Merck Serono's head of global development, in a
ZymoGenetics and Merck Serono Initiate Phase 2/3 Clinical Trial of...
www.finanznachrichten.de
Anton Hoos, M.D., Merck Serono's Head of Global Development, added: “This study forms part of our ongoing development program with atacicept ...
Cetuximab ups survival rate in head and neck cancer: Study
test.pharmabiz.com
... were published in the New England Journal of Medicine in 2006," said Dr Anton Hoos, executive vice president, Global Development, Merck Serono. › news
Merck KGaA schließt Rekrutierung für REFLEX-Studie mit Rebif ab...
www.aktiencheck.de
... an Multipler Sklerose zu erkranken", sagte Anton Hoos, Leiter der weltweiten klinischen Entwicklung von Merck Serono. "Allerdings muss auf ...
DIA Panellists to Face Rapid-fire Questions on Patient Engagement
www.prnewswire.co.uk
industry (Anton Hoos, Head of Medical Affairs, Amgen GmbH, ...
Merck Serono begins new Phase II/III trial of atacicept in lupus -...
www.pharmatimes.com
Merck Serono and partner Zymogenetics say they have started a mid-stage trial to evaluate the safety and efficacy of their investigational compound atacicept...
Merck Serono Completes Enrollment In The REFLEX Trial Of ...
www.science20.com
"It has been demonstrated that treatment with interferon beta can reduce the risk of developing multiple sclerosis," said Anton Hoos, Executive Vice ... › merc...
Past Events | Page 16 | NEWDIGS - Hopewell Partners
www.hopewellpartners.com
... Germany); Tomas Salmonson (CHMP/EMA); Carole Longson (NICE); Chris James (Motor Neurone Disease Association, United Kingdom); Anton Hoos (GSK). › ...
Patient engagement was a highlight of #DIA2017
medcitynews.com
— Anton Hoos, chief of medical for Amgen in Europe, agreed. Organizations across the board need to move together to involve patients in drug ... ›
Patients as Partners Europe Crunchbase
www.crunchbase.com
Speakers: Anton Hoos, Annick Anderson. Tuesday January 23, at 8:00 am (ends Wednesday January 24, at 5:00 pm). Read More ... › event
Merck Serono Announces Initiation Of Phase II Clinical Trial Of...
www.science20.com
"This trial with atacicept underlines Merck Serono's long-term commitment to patients with multiple sclerosis," said Dr. Anton Hoos, Head of ...
Merck Serono Announces Initiation Of Second Phase II/III Clinical...
www.science20.com
"Atacicept has the potential to alter the course of SLE, a complex and devastating disease," said Anton Hoos, M.D., Merck Serono's Head of ...
What do stakeholders expect from patient engagement - Cvent
custom.cvent.com
2018 · Zitiert von: 19 — Executive Director4 | Anton Hoos MD, Head of Medical5 | Marc Boutin JD, Chief. Executive6 | Jan Geissler Dipl-Kfm, Futures Group Chair › files › Event
FDA officials see 'missed opportunity' with patient outcomes in ...
www.biopharmadive.com
— “If every company develops their own outcome set, it will just not fly,” said Anton Hoos of Patient Focused Medicine Development. › ...
Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in...
press.abc-directory.com
"It has been demonstrated that treatment with interferon beta can reduce the risk of developing multiple sclerosis," said Anton Hoos, Executive Vice President, Global
pharma-tec.net - Donnerstag, :08
www.pharma-tec.net
„Diese Studie mit Atacicept unterstreicht das anhaltende Engagement von Merck Serono für Patienten mit Multipler Sklerose“, sagte Dr. Anton Hoos, Leiter der
sortiert nach Relevanz / Datum